Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

President Joe Biden told Indo-Pacific allies on Saturday that he believes China’s increasing military assertiveness is an effort to test the region at a turbulent moment for Beijing. Biden’s comments ...

UNITED NATIONS (AP) — Facing a swirl of conflicts and crises across a fragmented world, leaders attending this week’s annual ...

During HUAWEI CONNECT 2024, Huawei Cloud hosted a Summit themed "One Step to Intelligence, One Leap to Excellence", gathering ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...